Fewer than a dozen COVID-19 vaccines around the world have now reached the phase three stage, which means they are being trialled in human volunteers. 

One is made by Sinovac, a China-based biopharmaceutical company, which is conducting human trials in Brazil, Turkey and Indonesia.

Helen Yang, Senior Director of Global Strategy and Business Development at Sinovac tells The Agenda with Stephen Cole that the firm is expecting the first set of useful data from these trials by the end of November or early December. 

Yang says cooperation will be key for it to be a success as, "Only a global partnership can make things happen."

CLICK: For more stories from The Agenda with Stephen Cole